Core Laboratories Inc.

NYSE:CLB Voorraadrapport

Marktkapitalisatie: US$953.6m

Core Laboratories Balans Gezondheid

Financiële gezondheid criteriumcontroles 4/6

Core Laboratories heeft een totaal eigen vermogen van $256.4M en een totale schuld van $139.9M, wat de schuld-eigenvermogensverhouding op 54.5% brengt. De totale activa en totale passiva bedragen respectievelijk $600.5M en $344.0M. De EBIT Core Laboratories is $56.2M waardoor de rentedekking 4.2 is. Het heeft contanten en kortetermijnbeleggingen van $21.5M.

Belangrijke informatie

54.5%

Verhouding schuld/eigen vermogen

US$139.87m

Schuld

Rente dekkingsratio4.2x
ContantUS$21.47m
AandelenUS$256.42m
Totaal verplichtingenUS$344.05m
Totaal activaUS$600.47m

Recente financiële gezondheidsupdates

Is Core Laboratories (NYSE:CLB) Using Too Much Debt?

Nov 12
Is Core Laboratories (NYSE:CLB) Using Too Much Debt?

We Think Core Laboratories (NYSE:CLB) Can Stay On Top Of Its Debt

Jul 15
We Think Core Laboratories (NYSE:CLB) Can Stay On Top Of Its Debt

Recent updates

Is Core Laboratories (NYSE:CLB) Using Too Much Debt?

Nov 12
Is Core Laboratories (NYSE:CLB) Using Too Much Debt?

Is Core Laboratories Inc. (NYSE:CLB) Trading At A 38% Discount?

Sep 19
Is Core Laboratories Inc. (NYSE:CLB) Trading At A 38% Discount?

What You Can Learn From Core Laboratories Inc.'s (NYSE:CLB) P/E

Aug 14
What You Can Learn From Core Laboratories Inc.'s (NYSE:CLB) P/E

We Think Core Laboratories (NYSE:CLB) Can Stay On Top Of Its Debt

Jul 15
We Think Core Laboratories (NYSE:CLB) Can Stay On Top Of Its Debt

These Return Metrics Don't Make Core Laboratories (NYSE:CLB) Look Too Strong

Jun 25
These Return Metrics Don't Make Core Laboratories (NYSE:CLB) Look Too Strong

It's Unlikely That Core Laboratories Inc.'s (NYSE:CLB) CEO Will See A Huge Pay Rise This Year

May 02
It's Unlikely That Core Laboratories Inc.'s (NYSE:CLB) CEO Will See A Huge Pay Rise This Year

Is Core Laboratories Inc. (NYSE:CLB) Trading At A 25% Discount?

Mar 26
Is Core Laboratories Inc. (NYSE:CLB) Trading At A 25% Discount?

Why We're Not Concerned About Core Laboratories Inc.'s (NYSE:CLB) Share Price

Mar 02
Why We're Not Concerned About Core Laboratories Inc.'s (NYSE:CLB) Share Price

Core Laboratories: EPS Miss, But Beneficial Outlook About Exploration Efforts

Nov 09

Returns On Capital At Core Laboratories (NYSE:CLB) Paint A Concerning Picture

Sep 08
Returns On Capital At Core Laboratories (NYSE:CLB) Paint A Concerning Picture

Core Laboratories: 'Spooked The Herd' In June, Things Might Be Looking Up

Aug 16

Core Laboratories Inc.'s (NYSE:CLB) Earnings Haven't Escaped The Attention Of Investors

Jul 05
Core Laboratories Inc.'s (NYSE:CLB) Earnings Haven't Escaped The Attention Of Investors

The Returns On Capital At Core Laboratories (NYSE:CLB) Don't Inspire Confidence

May 25
The Returns On Capital At Core Laboratories (NYSE:CLB) Don't Inspire Confidence

Analyse van de financiële positie

Kortlopende schulden: De korte termijn activa ( $235.2M ) CLB } overtreffen de korte termijn passiva ( $94.9M ).

Langlopende schulden: De kortetermijnactiva van CLB ( $235.2M ) dekken de langetermijnschulden ( $249.1M ) niet.

Schuld/ eigen vermogen geschiedenis en analyse

Schuldniveau: De netto schuld/eigen vermogen ratio ( 46.2% ) CLB wordt als hoog beschouwd.

Schuld verminderen: De schuld/eigen vermogen-ratio van CLB is de afgelopen 5 jaar gedaald van 153.4% naar 54.5%.

Schuldendekking: De schuld van CLB wordt goed gedekt door de operationele kasstroom ( 39.5% ).

Rentedekking: De rentebetalingen op de schuld van CLB worden goed gedekt door EBIT ( 4.2 x dekking).

Balans

Ontdek gezonde bedrijven

7D

1Y

7D

1Y

7D

1Y